Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 691 clinical trials
18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer

To study the added value of 18F-PSMA-1007 PET to mpMRI in the detection of local prostate cancer lesions.

digital rectal examination
positron emission tomography
pet/ct scan
multiparametric magnetic resonance imaging
  • 0 views
  • 19 Feb, 2024
PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

Open-label, multicenter, dose titration and expansion three-arm trial to evaluate the safety, tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1) in patients with metastatic castration resistant prostate cancer (mCRPC) W_pro1 in combination with goserelin acetate with or without cemiplimab, in patients with high-risk, localized prostate cancer (LPC)

testosterone
enzalutamide
luteinising hormone
HIV Infection
lung disease
  • 2 views
  • 19 Feb, 2024
Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

This is a single-arm Phase II clinical trial assessing the clinical efficacy of prostate specific membrane antigen (PSMA) PET/MR guided MR-LINAC based SBRT-SIB with planned accrual of 50 patients.

metastasis
hbed-cc
adenocarcinoma
adenocarcinoma of prostate
stereotactic body radiation therapy
  • 16 views
  • 19 Feb, 2024
Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer

This is a phase I, clinical research study of EPI-7386, an investigational drug being studied as a treatment for patients with prostate cancer. All patients in the study will receive EPI-7386. Since this is the first study of EPI-7386 in humans, there is no information about how it affects people …

diphosphonates
castration-resistant prostate cancer
soft tissue disease
bone scan
metastasis
  • 0 views
  • 19 Feb, 2024
Lutetium-177-PSMA-I&T in Oligo-metastatic Hormone Sensitive Prostate Cancer

  Radioligand therapy (RLT) using Lutetium-177 labelled PSMA is a promising new therapeutic approach to treat metastatic prostate cancer. This tumor-specific treatment is directed against prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells.

testosterone
hormone therapy
enzalutamide
immunological adjuvant
white blood cell count
  • 4 views
  • 19 Feb, 2024
18F-DCFPyL PET/CT Impact on Treatment Strategies for Patients With Prostate Cancer

The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding …

adenocarcinoma of prostate
ct scan
positron emission tomography
metastatic prostate cancer
adenocarcinoma
  • 0 views
  • 19 Feb, 2024
Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer

This is a first in human study to assess the safety, tolerability, PK, PD and preliminary efficacy of CC-94676 in men with progressive metastatic castration-resistant prostate cancer.

testosterone
serum testosterone
hormone therapy
enzalutamide
cancer
  • 0 views
  • 19 Feb, 2024
A Study to Explore Personalized Treatment for Patients with Recurrent Gynecological Malignancies Based on MTB (RWS-MTB)

The main question it aims to answer is:Will genomic sequencing and molecular tumor boards lead to clinical responses in patients with recurrent ovarian, cervical, or endometrial cancer? The retrospective arm will analyze data from patients with recurrent gynecological malignancies (ovarian, cervical, or endometrial) who underwent multidisciplinary consultations at our institution …

  • 0 views
  • 17 Jan, 2025
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with BAY1895344 in combination with niraparib. In addition researchers want to find for patients the optimal dose of BAY1895344 in combination with niraparib, how the drug is tolerated and …

ovarian cancer
measurable disease
primary peritoneal carcinoma
cancer
serum pregnancy test
  • 0 views
  • 19 Feb, 2024
Expanded Access of Omidubicel for Allogeneic Transplantation in Patients With Hematological Malignancies

Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.

cancer
allogeneic transplantation
hematologic malignancy
investigational treatment
  • 0 views
  • 19 Feb, 2024